CAR T Cells for Cancer Immunotherapy Current Challenges and Future Perspectives
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 120
Special Issue Editors
Interests: immunotherapy; CAR T cells; solid tumors; acute leukemia; hematopoietic stem cell transplantation; oncolytic viruses
Special Issues, Collections and Topics in MDPI journals
Interests: immunotherapy; CAR T cells; solid tumors; acute leukemia; hematopoietic stem cell transplantation; oncolytic viruses
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immunotherapy was a major breakthrough in the treatment of patients affected by malignancies. One of the most promising forms of immunotherapy to date is that using chimeric antigen receptor (CAR)-modified T cells, which redirects the specificity of T cells to an antigen expressed by tumor cells in an MHC-independent fashion. The success of the approach, mainly in the hematological field, is confirmed by the various CAR T cell platforms that have been approved by American and European regulatory agencies in the last 6 years. Moreover, recently, CAR T cells also resulted in promising efficacy in different settings, such as the treatment of immune-mediated disorders with a documented pathogenic role of B cells, including, but not limited to, systemic lupus erythematosus.
Together with the great success and with the new potential applications of the approach, limitations of the efficacy of CAR T cells have also emerged. In this Special Issue, we will evaluate CAR T cell approaches representing an innovation in the field, either in terms of proof-of-concept of new indications or in terms of new construct and/or manufacturing techniques. We invite original research papers, brief research reports, reviews and professional opinions that will address these important aspects.
Dr. Francesca Del Bufalo
Guest Editor
Marco Becilli
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- CAR T cells
- immunotherapy
- acute leukemia
- lymphoma
- myeloma
- systemic lupus erythematosus
